检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 157-171 doi: 10.1007/s11684-013-0272-4
Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant diseases worldwide. The current staging criteria do not fully capture the complexity of this disease. Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generation sequencing, have recently been developed to facilitate effectively its molecular classification. The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecular classification scheme may promote individualized treatment and improve clinical outcomes. This review focuses on the molecular classification of NSCLC based on gene expression microarray technology reported during the past decade, as well as their applications for improving the diagnosis, staging and treatment of NSCLC, including the discovery of prognostic markers or potential therapeutic targets. We highlight some of the recent studies that may refine the identification of NSCLC subtypes using novel techniques such as epigenetics, proteomics, or deep sequencing.
关键词: non-small-cell lung cancer molecular typing individualized medicine molecular-targeted therapy gene expression profiling
Molecular classification and molecular targeted therapy of cancer
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 147-149 doi: 10.1007/s11684-013-0274-2
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
《医学前沿(英文)》 2009年 第3卷 第3期 页码 256-264 doi: 10.1007/s11684-009-0052-3
关键词: target therapy gynecologic malignant tumors clinical trail molecular medicine
Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen
《医学前沿(英文)》 2011年 第5卷 第4期 页码 379-387 doi: 10.1007/s11684-011-0162-6
关键词: nanoparticles superparamagnetic iron oxide targeted therapy molecular imaging cancer
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
《医学前沿(英文)》 2020年 第14卷 第6期 页码 689-700 doi: 10.1007/s11684-020-0759-8
关键词: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
null
《医学前沿(英文)》 2015年 第9卷 第2期 页码 134-138 doi: 10.1007/s11684-015-0396-9
Drug resistance is a major factor that limits the efficacy of targeted cancer therapies. In this review, we discuss the main known mechanisms of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted therapeutic agent in current clinical use. Here we focus on bypass track resistance, which involves the activation of alternate signaling molecules by tumor cells to bypass inhibition and maintain signaling output, and consider the problems of signaling pathway redundancy and how the activation of different receptor tyrosine kinases translates into intracellular signal transduction in different cancer types. This information is presented in the context of research strategies for the discovery of new targets for pharmacological intervention, with the goal of overcoming resistance in order to improve patient outcomes.
关键词: targeted therapy drug resistance receptor tyrosine kinases cancer
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
《医学前沿(英文)》 2021年 第15卷 第2期 页码 221-231 doi: 10.1007/s11684-020-0812-7
关键词: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
《医学前沿(英文)》 2019年 第13卷 第4期 页码 427-437 doi: 10.1007/s11684-018-0672-6
关键词: targeted therapy desmoid-type fibromatosis tyrosine kinase inhibitor γ-secretase inhibitor
Progress and challenges in RET-targeted cancer therapy
《医学前沿(英文)》 2023年 第17卷 第2期 页码 207-219 doi: 10.1007/s11684-023-0985-y
关键词: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug resistance
《医学前沿(英文)》 2023年 第17卷 第3期 页码 493-502 doi: 10.1007/s11684-022-0946-x
关键词: ALK fusion next-generation sequencing fluorescence in situ hybridization immunohistochemistry variant allele frequency intratumoral heterogeneity targeted therapy
《医学前沿(英文)》 2023年 第17卷 第2期 页码 275-289 doi: 10.1007/s11684-022-0945-y
关键词: epidermal growth factor receptor ErbB receptors HM781-36B nasopharyngeal carcinoma molecular targeted therapy cisplatin
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells
XIONG Ying, GUO Wen, LI Ting, LI Ke
《医学前沿(英文)》 2007年 第1卷 第3期 页码 304-307 doi: 10.1007/s11684-007-0058-7
关键词: control therapy influence Survivin-1 colorectal carcinoma
抑制FLT3 ——急性髓系白血病分子靶向治疗的原型 Review
Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert
《工程(英文)》 2021年 第7卷 第10期 页码 1354-1368 doi: 10.1016/j.eng.2021.05.020
急性髓系白血病(AML)的现代治疗始于1973年,首例柔红霉素和阿糖胞苷联合治疗法的成功随后拯救了大约45%的患者。准确的AML诊断依赖于形态学方法,其最初仅由细胞化学手段辅助。与急性淋巴细胞白血病(ALL)不同,至少在20世纪70年代和80年代,免疫分型在AML的诊断中几乎不起作用。可靠的细胞遗传学方法的出现为AML的预后发展带来了翻天覆地的变化。通过核型分析,可以对不同的AML实现分类与分层,以进行各种治疗。借助细胞上抗原标记物的免疫表型鉴定,独特的突变图谱可以里程碑式地进一步对 AML 患者进行分类。所有的这些进展都随着对肿瘤负荷[即微小残留病变(minimal residual disease, MRD)]的重要性的理解而成为AML患者管理的关键。MRD的疗效在过去10年迅速发展,其特异性从免疫分型的10-3发展到聚合酶链反应(PCR)的10-4(且仅对于部分AML患者有效),并最终在具有下一代测序(NGS)技术的灵敏度极高的细胞中发展至10-5甚至10-6。所有这些进步都促进了个性化医疗概念的发展,并带来了可以准确用于特定诊断亚型的靶向药物。可以精准预测与测量其响应。这些靶向药物现已成为AML管理的基础,其疗效显著提高,而毒性则显著下降。本文的重点是研究最为深入的AML靶向药物之一——FMS样酪氨酸激酶3(FLT3)抑制剂,它影响了AML的预后与治疗。作为已被批准的其他新兴靶向药物以及目前正在开发的靶向药物的原型,本文将选择性地对FLT3抑制剂展开详细讨论。
标题 作者 时间 类型 操作
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
null
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory
Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,
期刊论文
Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging
Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen
期刊论文
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
null
期刊论文
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
期刊论文
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao
期刊论文
Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy
期刊论文
A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma
期刊论文
Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells
XIONG Ying, GUO Wen, LI Ting, LI Ke
期刊论文